Affymax (AFFY) Continues Higher on OMONTYS Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts AFFY Hot Sheet
Join SI Premium – FREE
Affymax, Inc. (Nasdaq: AFFY) is showing continued strength Tuesday, following OMONTYS news issued earlier
According to a release Tuesday morning, Affymax and Takeda Pharmaceutical Company Limited, announced that OMONTYS (peginesatide) Injection is now available only for use in treating anemia due to chronic kidney disease (CKD) in adult patients on dialysis.
Shares are 10.8 percent higher on the session.
According to a release Tuesday morning, Affymax and Takeda Pharmaceutical Company Limited, announced that OMONTYS (peginesatide) Injection is now available only for use in treating anemia due to chronic kidney disease (CKD) in adult patients on dialysis.
Shares are 10.8 percent higher on the session.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lumentum's optical components sold out through early 2029: CEO
- Musk rules out TSMC role in Terafab operations; Intel gains
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
